J
Jie Qing Chen
Researcher at University of Texas MD Anderson Cancer Center
Publications - 20
Citations - 2513
Jie Qing Chen is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Immunotherapy & Melanoma. The author has an hindex of 9, co-authored 18 publications receiving 1990 citations. Previous affiliations of Jie Qing Chen include Merck Serono & University of Texas Health Science Center at Houston.
Papers
More filters
Journal ArticleDOI
Loss of PTEN Promotes Resistance to T Cell–Mediated Immunotherapy
Weiyi Peng,Jie Qing Chen,Chengwen Liu,Shruti Malu,Caitlin Creasy,Michael T. Tetzlaff,Chunyu Xu,Jodi A. McKenzie,Chunlei Zhang,Xiaoxuan Liang,Leila Williams,Wanleng Deng,Guo Chen,Rina M. Mbofung,Alexander J. Lazar,Carlos A. Torres-Cabala,Zachary A. Cooper,Pei-Ling Chen,Trang N. Tieu,Stefani Spranger,Xiaoxing Yu,Chantale Bernatchez,Marie-Andree Forget,Cara Haymaker,Rodabe N. Amaria,Jennifer L. McQuade,Isabella C. Glitza,Tina Cascone,Haiyan S. Li,Lawrence N. Kwong,Timothy P. Heffernan,Jianhua Hu,Roland L. Bassett,Marcus Bosenberg,Scott E. Woodman,Willem W. Overwijk,Gregory Lizée,Jason Roszik,Thomas F. Gajewski,Jennifer A. Wargo,Jeffrey E. Gershenwald,Laszlo Radvanyi,Michael A. Davies,Patrick Hwu +43 more
TL;DR: It is demonstrated that loss of PTEN in tumor cells in preclinical models of melanoma inhibits T cell-mediated tumor killing and decreases T-cell trafficking into tumors, and support the rationale to explore combinations of immunotherapies and PI3K-AKT pathway inhibitors.
Journal ArticleDOI
PD-L1 expression and prognostic impact in glioblastoma.
Edjah K. Nduom,Jun Wei,Nasser K. Yaghi,Neal Huang,Ling Yuan Kong,Konrad Gabrusiewicz,Xiaoyang Ling,Shouhao Zhou,Cristina Ivan,Jie Qing Chen,Jared K. Burks,Gregory N. Fuller,George A. Calin,Charles A. Conrad,Caitlin Creasy,Krit Ritthipichai,Laszlo Radvanyi,Amy B. Heimberger +17 more
TL;DR: The incidence of PD-L1 expression in GBM patients is frequent but is confined to a minority subpopulation, similar to other malignancies that have been profiled for PD- L1 expression.
Journal ArticleDOI
BRAF inhibition increases tumor infiltration by T cells and enhances the antitumor activity of adoptive immunotherapy in mice.
Chengwen Liu,Weiyi Peng,Chunyu Xu,Yanyan Lou,Minying Zhang,Jennifer A. Wargo,Jie Qing Chen,Haiyan S. Li,Stephanie S. Watowich,Yan Yang,Dennie T. Frederick,Zachary A. Cooper,Rina M. Mbofung,Mayra Whittington,Keith T. Flaherty,Scott E. Woodman,Michael A. Davies,Laszlo Radvanyi,Willem W. Overwijk,Gregory Lizée,Patrick Hwu +20 more
TL;DR: Analysis of human melanoma patient tumor biopsies before and during BRAF inhibitor treatment showed downregulation of VEGF consistent with the preclinical murine model, providing a strong rationale to evaluate the potential clinical application of combining BRAF inhibition with T-cell–based immunotherapy for the treatment of patients with melanoma.
Journal ArticleDOI
Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
Richard Wu,Marie Andrée Forget,Jessica Ann Chacon,Jessica Ann Chacon,Chantale Bernatchez,Cara Haymaker,Jie Qing Chen,Patrick Hwu,Laszlo Radvanyi,Laszlo Radvanyi +9 more
TL;DR: A model in which both effector-memory and more differentiated effector T cells ultimately may need to cooperate to mediate long-term tumor control in responding patients is presented, predicting that TILs will indeed emerge to become an approved treatment in the upcoming years through pivotal clinical trials.
Journal ArticleDOI
Visualizing fewer than 10 mouse T cells with an enhanced firefly luciferase in immunocompetent mouse models of cancer
Brian Rabinovich,Yang Ye,Tamara Etto,Jie Qing Chen,Hyam I. Levitsky,Willem W. Overwijk,Laurence J.N. Cooper,Juri G. Gelovani,Patrick Hwu +8 more
TL;DR: expression of enhanced ffLuc in mouse T cells permitted the tracking of adoptively transferred T cells infiltrating sites of vaccination and preestablished tumors, and enumerate infiltrating mouse lymphocytes constituting <0.3% of total tumor cellularity, representing a significant improvement over standard methods of quantitation including flow cytometry.